Page 47 - Read Online

Page 12 of 12 Zhao et al. Vessel Plus 2021;5:10 I http://dx.doi.org/10.20517/2574-1209.2020.77

15. Kim JT, Fonarow GC, Smith EE, et al. Treatment with tissue plasminogen activator in the golden hour and the shape of the 4.5-hour time-
benefit curve in the National United States Get with the guidelines-stroke population. Circulation 2017;135:128-39.
16. Zhao H, Coote S, Pesavento L, et al. Prehospital idarucizumab prior to intravenous thrombolysis in a mobile stroke unit. Int J Stroke
2019;14:265-9.
17. Fassbender K, Grotta JC, Walter S, Grunwald IQ, Ragoschke-Schumm A, Ragoschke-Schumm A. Mobile stroke units for prehospital
thrombolysis, triage, and beyond: benefits and challenges. Lancet Neurol 2017;16:227-37.
18. Nogueira RG, Jadhav AP, Haussen DC, et al; DAWN Trial Investigators. Thrombectomy 6 to 24 hours after stroke with a mismatch
between deficit and infarct. N Engl J Med 2018;378:11-21.
19. Albers GW, Marks MP, Kemp S, et al; DEFUSE 3 Investigators. Thrombectomy for stroke at 6 to 16 hours with selection by perfusion
imaging. N Engl J Med 2018;378:708-18.
20. Czap AL, Grotta JC, Parker SA, et al. Emergency department door-to-puncture time since 2014. Stroke 2019;50:1774-80.
21. Patel P, Sheikhi L, Mullaguri N, et al. Abstract WP226: bypassing interhospital transfers for large vessel occlusions in the era of mobile
stroke units. Stroke 2018;49.
22. Kerrigan D, Di Lorenzo R, Nour M, Russman A, Uchino K, Hussain MS. Abstract TMP19: mobile stroke units have higher rates of
recanalization of emergent large vessel occlusion. Stroke 2019;50.
23. Saver JL, Goyal M, van der Lugt A, et al; HERMES Collaborators. Time to treatment with endovascular thrombectomy and outcomes
from ischemic stroke: a meta-analysis. JAMA 2016;316:1279-88.
24. Meretoja A, Keshtkaran M, Saver JL, et al. Stroke thrombolysis: save a minute, save a day. Stroke 2014;45:1053-8.
25. Meretoja A, Keshtkaran M, Tatlisumak T, Donnan GA, Churilov L. Endovascular therapy for ischemic stroke: save a minute-save a week.
Neurology 2017;88:2123-7.
26. Emberson J, Lees KR, Lyden P, et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with
alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet 2014;384:1929-35.
27. Al-shahi Salman R, Frantzias J, Lee RJ, et al. Absolute risk and predictors of the growth of acute spontaneous intracerebral haemorrhage:
a systematic review and meta-analysis of individual patient data. Lancet Neurol 2018;17:885-94.
28. Sprigg N, Flaherty K, Appleton JP, et al. Tranexamic acid for hyperacute primary intracerebral haemorrhage (TICH-2): an international
randomised, placebo-controlled, phase 3 superiority trial. Lancet 2018;391:2107-21.
29. Gladstone DJ, Aviv RI, Demchuk AM, et al. Effect of recombinant activated coagulation factor VII on hemorrhage expansion among
patients with spot sign-positive acute intracerebral hemorrhage: the SPOTLIGHT and STOP-IT randomized clinical trials. JAMA Neurol
2019;76:1493-501.
30. Mayer SA, Brun NC, Begtrup K, et al. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl
J Med 2008;358:2127-37.
31. Li Q, Warren AD, Qureshi AI, et al. Ultra-early blood pressure reduction attenuates hematoma growth and improves outcome in
intracerebral hemorrhage. Ann Neurol 2020;88:388-95.
32. Connolly SJ, Crowther M, Eikelboom JW, et al. Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. N
Engl J Med 2019;380:1326-35.
33. Huttner HB, Schellinger PD, Hartmann M, et al. Hematoma growth and outcome in treated neurocritical care patients with intracerebral
hemorrhage related to oral anticoagulant therapy: comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and
prothrombin complex concentrates. Stroke 2006;37:1465-70.
34. Abid KA, Vail A, Patel HC, King AT, Tyrrell PJ, Parry-Jones AR. Which factors influence decisions to transfer and treat patients with
acute intracerebral haemorrhage and which are associated with prognosis? A retrospective cohort study. BMJ Open 2013;3:e003684.
35. John S, Stock S, Cerejo R, et al. Brain imaging using mobile CT: current status and future prospects. J Neuroimaging 2016;26:5-15.
36. Ma H, Campbell BCV, Parsons MW, et al. Thrombolysis guided by perfusion imaging up to 9 hours after onset of stroke. N Engl J Med
2019;380:1795-803.
37. Campbell BC, Weir L, Desmond PM, et al. CT perfusion improves diagnostic accuracy and confidence in acute ischaemic stroke. J
Neurol Neurosurg Psychiatry 2013;84:613-8.
38. Campbell BCV, Khatri P. Stroke. Lancet 2020;396:129-42.
39. Bowry R, Parker SA, Yamal JM, et al. Time to decision and treatment with tPA (tissue-type plasminogen activator) using telemedicine
versus an onboard neurologist on a mobile stroke unit. Stroke 2018;49:1528-30.
40. Winter B, Wendt M, Waldschmidt C, et al. 4G versus 3G-enabled telemedicine in prehospital acute stroke care. Int J Stroke
2019;14:620-9.
41. Krebes S, Ebinger M, Baumann AM, et al. Development and validation of a dispatcher identification algorithm for stroke emergencies.
Stroke 2012;43:776-81.
42. Kim J, Easton D, Zhao H, et al. Economic evaluation of the Melbourne mobile stroke unit. Int J Stroke 2020;1747493020929944.
43. Wang S., Gum D., Merlin T. Comparing the ICERs in medicine reimbursement submissions to NICE and PBAC-Does the presence of an
explicit threshold affect the ICER proposed? Value Health 2018;21:938-43.
44. Gyrd-Hansen D, Olsen KR, Bollweg K, Kronborg C, Ebinger M, Audebert HJ. Cost-effectiveness estimate of prehospital thrombolysis:
results of the PHANTOM-S study. Neurology 2015;84:1090-7.
45. Reimer AP, Zafar A, Hustey FM, et al. Cost-consequence analysis of mobile stroke units vs. standard prehospital care and transport. Front
Neurol 2019;10:1422.